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Abstract: We studied absorption, efficacy, and tolerability in
Parkinson’s disease (PD) of a new preparation of apomor-
phine included in a microemulsion and administered by trans-
dermal route (Apo-MTD). Twenty-one PD patients were
treated with levodopa plus oral dopamine-agonists (T0), with
levodopa alone (T1), finally with levodopa plus Apo-MTD
(T2). Apo-MTD provided therapeutic plasma levels for many
hours, improved Unified Parkinson’s Disease Rating Scale III
scores, and reduced total duration of off periods compared to
T0 and T1. We concluded that Apo-MTD is absorbed and
demonstrates clinical efficacy and long action. Therefore, it
seems a promising add-on treatment for uncontrolled pro-
longed off phases in PD patients, but chronic tolerability needs
further study. © 2004 Movement Disorder Society
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Apomorphine (10,11-dihydroxyapomorphine) is a
well-known potent short-acting dopamine agonist at D1
and D2 dopamine receptors, and it was proposed as an
antiparkinsonian drug more than a century ago. It is
potentially a very useful adjunctive medication in par-
kinsonian patients with refractory motor fluctuations1,2;
unlike other currently available dopamine agonists, apo-
morphine is able to reverse bradykinesia when adminis-
tered alone; thus, it has been used for treatment of off
periods.3,4 Despite these favourable characteristics, its
clinical use for the treatment of Parkinson’s disease is
somewhat limited by its pharmacokinetic profile: a short
half-life of approximately 30 minutes, rapid clearance
from plasma, the absence of storage or retention in brain
regions, poor oral bioavailability (5%), and first-pass
hepatic metabolism are important limitations to chronic
oral treatment.5–7 Attempts have been made to overcome
these limits by using other routes of administration. The
subcutaneous route is able to avoid the first-pass hepatic
metabolism; by this route, apomorphine is quickly ab-
sorbed, with little regional retention, and peak plasma
levels achieved in 3 to 10 minutes in most patients;
significant variations in peak plasma levels among pa-
tients have been described.5,6 Unfortunately, its short
half-life and rapid clearance from plasma are still respon-
sible for a short clinical effect. For these reasons, at
present its use is limited to rapidly reversing off periods or
as a diagnostic tool.8,9 Subcutaneous administration of apo-
morphine by means of a microinfusor is able to give con-
stant therapeutic plasma levels of the drug, and it has been
successfully used in patients with advanced Parkinson’s
disease to reduce motor fluctuations or to guarantee a con-
tinuous dopaminergic stimulation during the transitory in-
terruption of levodopa (L-dopa) therapy (“drug holiday”).10
Nevertheless, this treatment sometimes cannot be longer
than a week due to the occurrence of local subcutaneous
nodules or other systemic side effects (nausea, sleepiness,
hallucination phenomena).10 Other routes of administration
such as sublingual, intranasal, and rectal, although promis-
ing, still remain of limited use. Absorption through the
sublingual route is slow, and bioavailability is less than
20%; irritation of the oral mucosa is the most important
factor that limits the use of this preparation only to selected
patients.11–13 Similarly, nasal stuffiness and crusting during
the intranasal route using a nebulized spray may occur and
may limit its use.6,14–17 The rectal route may provide pro-
longed effect and so may be a useful treatment in patients
with nocturnal impairments refractory to other agonists;
nevertheless, this route still remains impractical for most
patients.6,18,19 To exploit the favourable pharmacological
characteristics of apomorphine and overcome the pharma-
cokinetic limits, we studied a new pharmaceutical prepara-
tion of apomorphine dissolved in a thickened microemul-
sion,20 which may be administered by an epicutaneous–
transdermal route (Apo-MTD). Apomorphine was present
in the microemulsion as ion-pair complex with octanoate to
increase its lipophilicity and to diminish its dissociation.
The drug was completely dissolved in the microemulsion,
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and relatively high concentrations could be carried as a
consequence of the supersolvent properties of microemul-
sions. The dispersed phase, also acting as a reservoir, made
it possible to maintain an almost constant concentration in
the continuous phase. Pseudo–zero-order kinetics, thus,
could be achieved. The microemulsion was able to provide
in vitro, through hairless mouse skin, a flux of 88 g/h per
cm2 for 24 hours, with a kinetic release of pseudo–zero-
order and was chosen for in vivo study; all the components
were biocompatible and safe. The flux gave a first approx-
imation of the feasibility of the transdermal administration
in man. After the approval of the ethical committee, we
tested this preparation in a group of patients affected by
Parkinson’s disease and motor fluctuations, to verify (1)
primarily the absorption and the achievement of detectable
plasma levels of the drug; (2) secondarily its clinical effi-
cacy and tolerability.
PATIENTS AND METHODS
Apomorphine Microemulsion:
Components and Characterization
The Apo-MTD preparation consisted of R-apomor-
phine hydrochloride incorporated in a stable water-in-oil
microemulsion. Antioxidants were added to both the oil
phase and the aqueous phase to avoid oxidation of the
drug. Components of microemulsion were aqueous so-
lution containing 2% ascorbic acid (18.2%), oil phase
(isopropylmiristate-decanol 1:1.5 v/v containing 1% of
ascorbylpalmitate; 42.1%), R-apomorphine hydrochlo-
ride (3.9%), Epikuron 200 (7.3%), benzyl alcohol
(7.1%), octanoic acid (4.6%), sodium octanoate (3.5%),
sodium taurocholate (5.7%), 1,2-propanediol (7.6%).
The average droplet diameter was 74.9 nm, with a poly-
dispersity index of 0.20. The microemulsion was thick-
ened by adding 5.9% (w/w) of Aerosil 200 to the micro-
emulsion. The pH was 6.0. As control, a thickened
microemulsion not carrying apomorphine was also pre-
pared to verify the possible local side effects.
Apomorphine Microemulsion Application
Ten grams of Apo-MTD (apomorphine hydrochloride
3.9%) was applied to 100 cm2 skin area over the anterior
part of the chest, delimited by 1-mm-thick biocompatible
foam tapes and covered by a polyester-based membrane
(3M Scotchpak) and an occlusive membrane (Smith and
Nephew OpSite Flexigrid) to prevent evaporation of
some components. In these conditions, a single layer of
microemulsion (1 mm thick) was directly in contact with
the skin surface and acted as a reservoir of apomorphine.
The skin of patients was not pretreated.
Patients
Twenty-one consecutive patients affected by idiopathic
Parkinson’s disease who presented long-term L-dopa syn-
drome, failure of complete reduction of off periods with the
optimization of currently available antiparkinsonian drugs,
or positive response to apomorphine subcutaneous test
without severe side effects were selected for the study. All
patients gave informed consent and were evaluated for 5
days in basal conditions (T0 evaluation, with both L-dopa
and oral dopamine agonist therapy present). Unified Par-
kinson’s Disease Rating Scale (UPDRS) part III and the
tapping and walking test at regular intervals of 1 hour from
8:00 AM until 10:00 PM were performed. Mean scores values
in off and on conditions were calculated and a diary kept.
During this time, a dietary regimen was given to minimise
possible interference of amino acids on drug absorption.
Domperidone was started and maintained for the whole
period of study. L-Dopa therapy was not discontinued,
while dopamine agonists were gradually suspended at least
10 days before Apo-MTD administration. The other anti-
parkinsonian drugs, if present, were maintained. For 5 days
before Apo-MTD treatment (T1 evaluation, only L-dopa
therapy present), patients were re-evaluated as previously
described. On day 6, at 8:00 AM, Apo-MTDwas applied and
left for 12 hours (T2 evaluation, L-dopa and Apo-MTD
treatment present). Blood samples were collected at regular
intervals from 8:00 AM for 24 hours: every 15 minutes
during the 1st hour, every 30 minutes until the 3rd hour,
every hour until the 12th hour, again every 30 minutes until
the 14th hour, and finally on the 18th and 24th hour.
Apomorphine blood concentration was detected by high
performance liquid chromatography with electrochemical
detection according to the methods described.21 At the same
time of diurnal blood collections, UPDRS part III and the
tapping and walking tests were performed and results were
obtained for each patient, together with heart rate and blood
pressure parameters. UPDRS III and tapping test scores
obtained for each patient during Apo-MTD treatment (T2)
were compared to scores obtained on T0 and on T1 by
using the Wilcoxon rank test. Walking test time scores and
duration of off periods were compared using a paired t test;
P value less than 0.05 was considered statistically signifi-
cant. StatView software (SAS, Cary, NC) was used for
statistical analysis.
Pharmacokinetic Analysis
Plasma drug concentration data of the individual sub-
jects were analyzed by standard noncompartmental
methods. The individual Cmaxs and times to Cmax
(Tmax) were obtained. The area under the curve (AUC)
to the last measurable concentration was calculated with
the log–linear trapezoidal rule, and the absorption and
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elimination half-life determined. Pharmacokinetic pa-
rameters were correlated to UPDRS III scores, walking
and tapping test scores, and duration of off periods,
obtained on T2, using Spearman rank correlation test.
RESULTS
Clinical Characteristics of Patients
Clinical characteristics of parkinsonian patients are sum-
marized in Table 1. Mean age was 59.5 years, mean dura-
tion of illness 7.9 years, with a mean Hoehn–Yahr score
equal to 3.4; mean L-dopa daily dosage was 645 mg. All
patients presented long-term L-dopa syndrome character-
ized by predictable off and “wearing-off” phenomena, but
none of them presented unpredictable off or hallucinations.
Of 21 patients, 7 had peak-dose and plateau-dose dyskine-
sias, 6 patients presented nocturnal dystonias. All patients,
according to inclusion criteria, had a positive apomorphine
test (dose range, 1.5–4.5 mg) without severe side effects.
Pharmacokinetic Analysis
Apo-MTD pharmacokinetic analysis is summarized in
Table 2. In all patients except 2, apomorphine was de-
tected in blood samples after a variable lag-time from the
application of Apo-MTD. Epicutaneous–transdermal
apomorphine absorption was demonstrated to be rapid
(mean half-life of absorption  1.03 hours) with a vari-
ability among patients (half-life of absorption SD 1.39
hours). Mean Cmax was above therapeutic range (mean
Cmax  42.81  11.67 ng/ml); pharmacokinetic analy-
sis revealed a mean Tmax of 5.1  2.24 hours and a
mean half-life of elimination equal to 10.8  1.93 hours.
Figure 1 shows the mean time course of apomorphine
plasma levels after Apo-MTD application in 19 patients
(excluding the 2 patients with undetectable drug in
plasma), compared with apomorphine plasma profile af-
ter 3 mg of subcutaneous apomorphine test carried out in
1 patient. It is evident that the increase in the apomor-
phine plasma level reached therapeutic concentrations
after a mean latency of 45 minutes (range, 18–125 min-
utes). Stable concentrations of apomorphine, above ther-
apeutic range, were obtained until Apo-MTD was main-
tained. On the 12th hour, Apo-MTD was removed, and
during the next hours, apomorphine plasma concentra-
tion decreased at a rate comparable to that described for
subcutaneous administration.
Clinical Evaluation and Pharmacokinetic
Correlations
Differences between motor performances during Apo-
MTD treatment (T2 evaluation) and motor performances
obtained on T1 evaluation and on T0 evaluation are
summarized in Table 3 (the 2 patients with undetectable
drug in plasma are not included). Cmax and AUC ob-
tained after Apo-MTD administration in each patient
showed only a mild correlation, with mean UPDRS III
scores in the on condition on T2 obtained for each patient
(r  0.42; P  0.04 and r  0.38; P  0.06, respec-
tively), and a stronger correlation with mean tapping test
scores (r  0.52; P  0.03 and r  0.49; P  0.02,
respectively). Moreover, Cmax and AUC showed a good
correlation with the reduction of total duration of off
periods, calculated as the difference between the total
duration of off periods obtained on T1 and T2 for each
FIG. 1. Comparison of apomorphine plasma concentration–time pro-
file after application of a preparation of apomorphine included in a
microemulsion and administered by transdermal route (Apo-MTD)
(mean) and after apomorphine 3 mg administered by subcutaneous
(s.c.) route [HPLC method]. Time 0, Apo-MTD application; hour 12,
Apo-TD removal. Triangles, Apo-MTD; solid line, Apomorphine s.c.
TABLE 1. Clinical characteristics of patients
Patients, N (M/F) 21 (12/9)
Age, mean (yr) 59.5 (range,55–74)
Duration of illness, mean (yr) 7.9 (range,4–15)
L-Dopa dose/24h, mean (mg) 645 (range,250–1100)
Hoehn and Yahr score (mean) 3.4 (range,3–4)
Long-term L-dopa syndrome duration, mean
(yr)
3.4 (range,1–9)
Wearing off 21
Predictable off 21
Dyskinesias 7
Nocturnal dystonias 6
Unpredictable off 0
Hallucinations 0
Use of dopamine oral agonists 21
Use of COMT inhibitors 12
Use of seligiline 3
Values are expressed as number of patients, unless otherwise indi-
cated.
TABLE 2. Pharmacokinetic analysis
Mean SD Min Max
Cmax (ng/ml) 42.81 11.67 33.19 62.75
Tmax (hr) 5.1 2.24 1.2 6.1
AUC (ng/ml  hr) 639.34 115.77 528.91 826.00
Half-life of absorption (hr) 1.03 1.39 0.23 3.49
Half-life of elimination (hr) 10.80 1.93 8.19 13.43
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patient (r  0.56; P  0.02 and r  0.51; P  0.04,
respectively). On the contrary, Tmax did not show cor-
relations with UPDRS III scores, walking and tapping
test scores, or reduction of off periods duration on T2. No
relationship between pharmacokinetic parameters with
age or sex was found.
Overall Tolerability
In our study, Apo-MTD overall tolerability was good.
Considering systemic side effects, 6 patients (28.5%)
reported sleepiness during treatment, 1 patient (5%) pre-
sented mild orthostatic hypotension, 3 patients (14.2%)
had transient nausea easily controlled with domperidone.
Only in 1 case (5%) this side effect was not tolerated, and
Apo-MTD had to be discontinued. Nausea, but not sleep-
iness or orthostatic hypotension, was strictly related to
the highest plasma level of apomorphine. Among the 7
patients with dyskinesias, 2 showed a moderate worsen-
ing of the involuntary movements, but this worsening did
not cause excessive trouble for the patients and did not
lead to treatment interruption. No hallucination phenom-
ena occurred. Regarding local side effects, 15 patients
(71.4%) had a transient mild erythema at the site of
Apo-MTD application, with a complete regression
within 48 hours; in 2 patients, this erythema lasted more
than 3 days and required local therapy. In 7 patients, it
appeared to be particularly pronounced along the border
of the patch where the foam tapes were in contact with
skin. The microemulsion not carrying apomorphine, ap-
plied as control to 10 patients for the same time interval
used with the apomorphine-loaded microemulsion (12
hours), using the same adhesive system, gave a similar
reaction of the skin (erythema along the border of the
patch) in 3 patients, but the application of microemulsion
not carrying apomorphine on the skin without any de-
limiting foam tape and occlusive membrane did not
produce skin reactions in any patient.
DISCUSSION
The management of motor fluctuations in advanced
Parkinson’s disease still represents a major problem, and
several therapeutic strategies have been proposed: con-
trolled-release preparations of L-dopa, continuous infu-
sion of L-dopa and apomorphine, and additional therapy
with COMT inhibitors or dopamine agonists.1,22–25 Even
if apomorphine is a potent dopamine agonist, its practical
use for the treatment of motor fluctuations in Parkinson’s
disease has been limited to date by its short half-life and
local side effects.11,14,15 Apo-MTD seems to overcome
some of these limitations. Pharmacokinetic analysis
demonstrates that, in most patients, Apo-MTD is ab-
sorbed by the epicutaneous–transdermal route. This find-
ing is in contrast with other previous reports, where the
transdermal route did not result in detectable plasma
levels of apomorphine6 or no apomorphine could be
transported passively through the skin.26 This difference
may be due to the apomorphine dosage, or it may be
related to the particular pharmaceutical preparation used
in our study: apomorphine was present in the microemul-
sion as ion-pair complex with octanoate to increase its
lipophilicity and to diminish its dissociation. The forma-
tion of an ion pair is presumably the main reason for the
facilitated transport of apomorphine through the skin.
Cmax after Apo-MTD administration (42.81  11.67
ng/ml) proves to be comparable to that of Cmax after
administration by the subcutaneous and sublingual routes
as reported in the literature (approximately 30 ng/ml for
both routes).6,13 As expected, Tmax for transdermal ab-
sorption (5.1 hours) is not as short as described for
subcutaneous and sublingual routes (Tmax of approxi-
TABLE 3. Clinical evaluation of patients in on and off conditions during L-dopa plus Apo-MTD treatment (T2) compared with
L-dopa alone (T1) and L-dopa plus oral dopamine agonists therapy (T0)
T0 T1 T2
On Off On Off On Off
UPDRS-III score 12.6 8.9 32.3  8.4 13.3  5.1 36.6  9.8 11.8 7.6 30.1 10.7a
Tapping test score
(taps/min) 118.3 32.6 77.2  31.8 113.4  26.5 62.1 23.1 120.1  31.9 78.7 21.5b
Walking test (sec) 16.1  3.1 — 15.8  3.1 — 15.4  2.3 —
Total duration of off
periods (hr) 4.6  2.6 6.6 3.4 3.1 1.2c,d
Values are expressed as mean  SD.
T0, L-dopa plus oral dopamine agonists therapy; T1, L-dopa alone; T2, L-dopa plus Apo- MTD treatment.
aP  0.04 compared to T1 in off conditions
bP  0.02 compared to T1 in off conditions
cP  0.0001 compared to T1
dP  0.02 compared to T0
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mately 20 minutes and 45 minutes, respectively, with
large variability among patients according to different
studies).6,13 Nevertheless therapeutic concentration after
Apo-MTD administration is achieved quite rapidly and
much earlier than Tmax (mean latency time for the
therapeutic concentration equal to 45 minutes), and after
this time, apomorphine concentration remains quite sta-
ble and above the therapeutic threshold for several hours
(half-life of elimination equal to 10.8 hours). Variability
of all the pharmacokinetic parameters is evident as
shown by high standard deviations, but it should be noted
that significant variations in peak plasma levels among
patients and variability of half-life of absorption have
also been described for subcutaneous injections and sub-
lingual administration.6,13 In vitro studies suggested that
the internal phase of microemulsion acts as a reservoir
and is able to provide through hairless mouse skin a
sustained flux of apomorphine for 24 hours with a kinetic
release of pseudo–zero-order.20 In vivo, several variables
are involved for transdermal absorption of the drug:
steady-state flux through intact skin primarily depends
on apomorphine concentration and application area.
Moreover, skin temperature and pH, together with local
blood flow, may play a role for in vivo apomorphine rate
of absorption. These variables may explain the wide
range of half-life of absorption found in our study; no
relationship between half-life of absorption and age was
found. It still remains unclear why two patients did not
present detectable apomorphine plasma levels; a further
explanation may include alterations of some components
due to a not perfectly occlusive patch. Even in the
presence of variability of pharmacokinetic parameters,
Apo-MTD in our study demonstrates the feasibility of
providing therapeutic apomorphine plasma levels for a
period of time much longer than any previous apomor-
phine preparations (several hours), corresponding to the
period of time that the Apo-MTD reservoir is maintained
on the skin. Regarding clinical evaluation, mean total
duration of off periods on T2 is by far shorter compared
to mean total duration of off periods on T1 (3.1  1.2
hours vs. 6.6  3.4 hours; P  0.0001). These findings
are somehow expected, because on T1, patients were
treated with L-dopa only, whereas on T2, Apo-MTD was
added. The two patients presenting undetectable apomor-
phine plasma levels did not show any amelioration of
motor performances on T2. Analysing T2 versus T0
clinical evaluation, Apo-MTD seems to show advantages
compared to standard oral dopamine-agonist treatments.
In off conditions, motor performances evaluated by
UPDRS III slightly improve on T2 compared with T0
clinical evaluation. Mean total duration of off periods is
shorter on T2 compared to T0, this difference being
statistically significant. The off phases are not completely
abolished by Apo-MTD, but no relationship with low
apomorphine plasma levels was found. Variability in
clinical response to apomorphine is reported for the other
routes of administration,6,13 mainly in patients with more
advanced disease under chronic L-dopa therapy. Our
group of patients presented severe motor fluctuations, so
the pharmacodynamic aspects of dopaminergic stimula-
tion and the degree of nigrostriatal degeneration may
play a role in our findings. It should be noted, however,
that T0 clinical evaluation is made after having already
optimized antiparkinsonian therapy; thus, Apo-MTD
seems to be able to reduce off periods more than any
other adjunctive antiparkinsonian drug previously used
for each patient (L-dopa dosage remained unchanged),
indicating a longer clinical benefit. That on period scores
are not further improved with Apo-MTD may be due to
an all-or-nothing way of action: therapeutic threshold
concentration has to be reached before clinical effect
occurs, but no further motor performance improvement
occurs after overcoming it.4,5 This mechanism of action
may also explain why apomorphine plasma levels show
only a mild correlation with UPDRS III scores obtained
in the on conditions on T2, whereas Cmax and AUC
show a good correlation with the reduction of total
duration of off periods. Overall tolerability was good in
our group of patients, and few and mild systemic side
effects have been noted. In the literature, apomorphine
side effects are reported to be more frequent,27,28 but this
difference can be partially explained by our inclusion
criteria requiring a positive apomorphine test without
severe side effects. Local tolerability was good for
1-day therapy (transient local erythema), but further
studies are necessary to verify tolerability during
chronic treatment.
In conclusion, our pilot study shows that this new
preparation of apomorphine administered by an epi-
cutaneous–transdermal route is able to provide a sus-
tained release of the drug and therapeutic plasma
levels for a prolonged period of time, by far longer
than any other dopamine-agonist preparation and com-
parable to continuous infusion of apomorphine. We
used an optimized group of patients, clinical evalua-
tion was not blinded, some findings relied on subjec-
tive measures (patient diary records), and the patch
was “homemade.” Nevertheless, the results are en-
couraging and Apo-MTD might become of value in
some L-dopa–treated patients suffering from uncon-
trolled “wearing-off” and prolonged off phenomena.
On the contrary, because of the lag-time of approxi-
mately 1 hour needed to reach therapeutic concentra-
tions, Apo-MTD does not seem to be the “ideal”
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preparation for the rapid relief of the off condition: in
this case, apomorphine administered by subcutaneous
route, having the most rapid absorption, still remains
the best choice. Local side effects are likely to be a
major problem in chronic treatment and need to be
further investigated. To verify the clinical findings of
our pilot study and tolerability in chronic use, we are
planning a randomized, double-blind clinical trial over
a longer time span with a larger group of patients and
comparisons with other selected antiparkinsonian ther-
apies (included repeated apomorphine SC administra-
tions). Future efforts should also be directed toward
the arrangement of a specific transdermal delivery
system that could permit standardized apomorphine
dosages and application areas.
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